
Real-World Abrocitinib Study Shows Most Patients Maintain Consistent Dosing in Atopic Dermatitis Treatment
Most patients with moderate-to-severe atopic dermatitis maintained consistent abrocitinib dosing throughout treatment in an international expanded access study simulating real-world use, with treatment-emergent adverse events accounting for dose changes in …